exon-skipping trial

Biotech company Prosensa says an analysis of drisapersen trials in Duchenne muscular dystrophy and a DMD natural history study will guide future exon-skipping drug trials

posted on November 19, 2013 - 1:00pm
In a Nov.
posted on October 1, 2010 - 12:25pm
QUEST Vol. 17, No. 4
Featured in this issue: First U.S. exon-skipping trial opens * Utah researchers seek families with Ullrich CMD or Bethlem myopathy * Acceleron receives Fast Track, Orphan Drug designations for ACE031 * BioMarin abandons BMN195 development